Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer faces lawsuits from 1,000 women alleging Depo-Provera birth control caused brain tumours, amid new research showing ...

Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many ...

Some women believe the birth control shot caused their meningiomas, a tumor that grows from the lining of the brain.

More than 1,000 women say Pfizer ignored evidence linking Depo-Provera to brain tumors—and used the FDA’s decision to protect itself.

Britain's medicines regulator said on Wednesday that final late-stage trial results from Pfizer and BioNTech's COVID-19 vaccine candidate were very encouraging, adding it would need to see the full ...

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

Americans headed to pharmacies for COVID-19 vaccines are running into roadblocks and confusion due to new U. guidance that ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...